Intraoperative argon endophotocoagulation for recurrent vitreous hemorrhage after vitrectomy for diabetic retinopathy
- PMID: 3812616
- DOI: 10.1016/s0002-9394(14)74219-9
Intraoperative argon endophotocoagulation for recurrent vitreous hemorrhage after vitrectomy for diabetic retinopathy
Abstract
We reviewed the medical records of 103 consecutive cases of vitrectomy performed for complications of diabetic retinopathy to determine if the introduction of argon laser endophotocoagulation had reduced the incidence of recurrent vitreous hemorrhage. Twenty-six eyes (48%) treated with endophotocoagulation and 35 (71%) eyes not receiving laser treatment had a recurrent hemorrhage. Follow-up was shorter for the eyes treated with endophotocoagulation, but a log-rank analysis to allow for this variable confirmed the benefit of laser photocoagulation (P less than .05). The proportion of eyes requiring surgical removal of the hemorrhage was also significantly lower in the group receiving endophotocoagulation (P less than .05). The beneficial effect of intraoperative laser treatment was independent of the amount of preoperative laser treatment, aphakia, and indications for the original vitrectomy surgery.
Similar articles
-
Vitreous hemorrhage after vitrectomy for diabetic retinopathy.Ophthalmology. 1984 Dec;91(12):1485-9. doi: 10.1016/s0161-6420(84)34099-4. Ophthalmology. 1984. PMID: 6521989
-
Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group.Arch Ophthalmol. 1986 Jan;104(1):34-41. doi: 10.1001/archopht.1986.01050130044017. Arch Ophthalmol. 1986. PMID: 2417579 Clinical Trial.
-
Fibrovascular ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: ultrasound biomicroscopy findings.Ophthalmology. 2004 Jun;111(6):1215-21. doi: 10.1016/j.ophtha.2003.08.043. Ophthalmology. 2004. PMID: 15177974
-
Management of proliferative diabetic retinopathy.Compr Ophthalmol Update. 2007 Sep-Oct;8(5):245-56. Compr Ophthalmol Update. 2007. PMID: 18201511 Review.
-
Vitrectomy surgery for diabetic retinopathy.Annu Rev Med. 1979;30:331-8. doi: 10.1146/annurev.me.30.020179.001555. Annu Rev Med. 1979. PMID: 400500 Review. No abstract available.
Cited by
-
Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.Cochrane Database Syst Rev. 2023 May 31;5(5):CD008214. doi: 10.1002/14651858.CD008214.pub4. Cochrane Database Syst Rev. 2023. PMID: 37260074 Free PMC article. Review.
-
Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab.Int Ophthalmol. 2012 Apr;32(2):135-44. doi: 10.1007/s10792-012-9541-5. Epub 2012 Mar 27. Int Ophthalmol. 2012. PMID: 22450558
-
Perfluorocarbon in vitreoretinal surgery and preoperative bevacizumab in diabetic tractional retinal detachment.World J Diabetes. 2014 Oct 15;5(5):724-9. doi: 10.4239/wjd.v5.i5.724. World J Diabetes. 2014. PMID: 25317250 Free PMC article.
-
Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.Cochrane Database Syst Rev. 2015 Aug 7;2015(8):CD008214. doi: 10.1002/14651858.CD008214.pub3. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2023 May 31;5:CD008214. doi: 10.1002/14651858.CD008214.pub4. PMID: 26250103 Free PMC article. Updated.
-
Long-term visual and retinopathy outcomes in a predominately type 2 diabetic patient population undergoing early vitrectomy and endolaser for severe vitreous haemorrhage.Eye (Lond). 2011 Jun;25(6):704-8; quiz 709. doi: 10.1038/eye.2011.65. Epub 2011 Apr 15. Eye (Lond). 2011. PMID: 21494282 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical